EGFR and lung carcinoma: Previous studies have identified that augmentation and mutations of EGFR play a critical role in tumorigenesis, and patients suffering from lung cancer harbouring this mutation or amplification benefited most from EGFR tyrosine kinase inhibitors (TKIs) [56, 57].